Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol

Introduction Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) faces significant challenges, including small patient populations, complex clinical trial design and difficulties in patient recruitment. Patients with Behçet’s disease (BD), idiopathic inflammatory my...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2025-02-01
Serie:	BMJ Open
Accesso online:	https://bmjopen.bmj.com/content/15/2/e089827.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!